Acute Myeloid Leukemia: Reviewing Current Best Practice and Exploring Novel Paradigms Ahead

Acute Myeloid Leukemia: Reviewing Current Best Practice and Exploring Novel Paradigms Ahead

Friday, December 9, 2022 in New Orleans, LA
Live Meeting -- Hyatt Regency New Orleans, 7:00 AM CT
Celestin EFGH

Agenda

  • Welcome and Introductions
  • Selecting Therapy for AML Without Predictive Biomarkers/Actionable Alterations
  • Selecting Therapy for AML With Predictive Biomarkers/Actionable Alterations
  • Final Thoughts
  • Audience Question and Answer

Faculty

Program Director
Daniel Pollyea, MD, MS

Professor of Medicine
Clinical Director of Leukemia Services
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado

Faculty
Courtney DiNardo, MD, MSCE

Associate Professor
Division of Cancer Medicine
Department of Leukemia
UT MD Anderson Cancer Center
Houston, Texas

Faculty
Eytan M. Stein, MD

Associate Attending Physician
Director
, Program for Drug Development in Leukemia
Leukemia Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with AML.

Target Audience
This educational program is intended for physicians, physician assistants, nurses, pharmacists, and other healthcare professionals who care for patients with AML.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Characterize the pathophysiologic, clinical, cytogenetic, and molecular profiles that guide therapy selection for patients with AML
  • Plan evidence-based therapeutic strategies for older patients, those with comorbidities, and/or those with secondary AML, using novel targeted agents or formulations and refinements of conventional chemotherapy
  • Select optimal maintenance treatment following induction therapy for patients who are not candidates for, or who choose not to proceed to, hematopoietic stem cell transplantation
  • Develop personalized treatment plans for therapeutically targetable molecular subsets of AML
  • Discuss promising novel agents in clinical development for the treatment of AML

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

NCCN designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
NCCN designates this educational activity for a maximum of 2.0 contact hours.

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 2.0 contact hours (0.2 CEUs) of continuing education credit. Universal Activity Number: JA4008196-0000-22-096-L01-P

Attention Pharmacists:
You must complete the post-test and evaluation within 30 days of the activity. Continuing pharmacy education credit is reported to the CPE Monitor once the post-test and evaluation are completed. Before completing these requirements, be sure your NCCN profile has been updated with your NABP e-profile ID and date of birth or your credit cannot be reported. If you have not already done so, please complete your e-profile at https://nabp.pharmacy/ to obtain your NABP e-Profile ID.

Physician Assistant Continuing Medical Education

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content will be reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, will be fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.